This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine
The main purpose of this page is to help laboratory buyers evaluate BPC-157 as a research material rather than as a medical product
United States: Not FDA-approved
Zhengzhou Changzhixing shows exceptionally high recent buyer activity, potentially indicating strong market traction for their infusion sets
Conflict of interest Flynn McGuire, Riley Martinez, Annika Lenz, Lee Skinner, and Dan Cushman declare that they have no conflict of interest
Other groups requiring careful evaluation include: Patients with a history of pancreatitis a causal relationship between incretin-based therapies and pancreatitis has not been definitively established, but UK SmPCs advise caution in those with a prior history